JPWO2019208627A1 - Composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength - Google Patents
Composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength Download PDFInfo
- Publication number
- JPWO2019208627A1 JPWO2019208627A1 JP2020515521A JP2020515521A JPWO2019208627A1 JP WO2019208627 A1 JPWO2019208627 A1 JP WO2019208627A1 JP 2020515521 A JP2020515521 A JP 2020515521A JP 2020515521 A JP2020515521 A JP 2020515521A JP WO2019208627 A1 JPWO2019208627 A1 JP WO2019208627A1
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- suppressing
- increasing
- soyasaponins
- strength
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本発明は、筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を有し、かつ、安全性が高い物質を有効成分として含む、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物、及び、筋肉量減少を抑制、筋力低下を抑制、筋肉量を増加又は筋力を増加させる方法を提供することを目的とする。本発明の筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物は、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を有効成分として含む。INDUSTRIAL APPLICABILITY The present invention has a muscle mass loss suppressing action, a muscle weakening suppressing action, a muscle mass increasing action or a muscle strength increasing action, and contains a highly safe substance as an active ingredient, for suppressing muscle mass loss and for suppressing muscle weakness. , A composition for increasing muscle mass or increasing muscle strength, and a method for suppressing muscle loss, suppressing muscle loss, increasing muscle mass or increasing muscle strength. The composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength of the present invention contains one or more of soyasapogenols and / or soyasaponins as an active ingredient.
Description
本発明は、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物に関する。本発明はまた、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加の方法に関する。また、本発明は、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加のための、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上の使用に関する。 The present invention relates to a composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength. The present invention also relates to methods of suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength. The present invention also relates to the use of one or more soyasapogenols and / or soyasaponins for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
日本のような人口構成における高齢者比率が高い国では、健康寿命の延長や日常生活の質(QOL)の向上が課題となっている。健康寿命の短縮の要因の一つとして、加齢に伴う筋肉量(筋量)の減少や筋力の低下が挙げられる。筋肉量や筋力の低下は、転倒リスク上昇、骨折等の怪我、長期臥床等を招く。怪我、病気等によって高齢者の活動量が減少すると、筋肉量や筋力が更に低下するという悪循環を招き、ロコモティブシンドローム等の原因となる。 In a country like Japan where the proportion of elderly people is high, extending healthy life expectancy and improving quality of life (QOL) are issues. One of the factors for shortening healthy life expectancy is a decrease in muscle mass (muscle mass) and a decrease in muscle strength with aging. Decreased muscle mass and strength lead to increased risk of falls, injuries such as fractures, and long-term bed rest. When the amount of activity of the elderly decreases due to injury, illness, etc., a vicious cycle is caused in which muscle mass and strength are further reduced, which causes locomotive syndrome and the like.
また、交通手段の発達等による運動不足や、手術後、病気の療養等において長期間安静が必要とされる場合等にも、筋肉量及び筋力が低下する。治癒後により早く日常生活に復帰するためには、筋肉量減少や筋力低下を抑制することが望まれる。 In addition, muscle mass and strength also decrease when exercise is insufficient due to the development of transportation means, or when long-term rest is required for medical treatment of illness after surgery. In order to return to daily life sooner after healing, it is desirable to suppress muscle mass loss and muscle weakness.
筋肉量又は筋力の低下抑制又は増加の手段の一つとして、リハビリテーション等の運動療法が行われている。一方、栄養学的観点から筋肉増強作用を有する成分の研究が行われている。例えば特許文献1には、マスリン酸及びオレアノール酸を摂取すると、摂取しない場合と比較して、トレーニング機器を使用しないレジスタンストレーニング後に骨格筋量が増加し、握力が強くなったことが記載されている。
Exercise therapy such as rehabilitation is performed as one of the means for suppressing or increasing the decrease or increase in muscle mass or strength. On the other hand, from a nutritional point of view, studies on components having a muscle-building effect are being conducted. For example,
運動療法は、時間的及び物理的な理由などから継続的な実施が難しく、高齢者等にとっては、身体的にも負担が大きい場合がある。このため安全性が高く、経口摂取等により筋肉量の減少抑制、筋力低下抑制、筋肉量増加又は筋力増加に有効な物質の開発が求められている。特許文献1に記載のマスリン酸及びオレアノール酸は、オリーブ等の植物に含まれる成分であり安全性が高いと考えられるが、より優れた筋肉量減少抑制作用、筋力低下抑制作用等を有する物質の開発が望まれている。
It is difficult to carry out exercise therapy continuously due to time and physical reasons, and it may be physically burdensome for the elderly and the like. Therefore, it is required to develop a substance having high safety and effective for suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength by oral ingestion or the like. Maslinic acid and oleanolic acid described in
本発明は、筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を有し、かつ、安全性が高い物質を有効成分として含む、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物を提供することを目的とする。また、本発明は、筋肉量減少を抑制、筋力低下を抑制、筋肉量を増加又は筋力を増加させる方法を提供することを目的とする。 INDUSTRIAL APPLICABILITY The present invention has a muscle mass loss suppressing action, a muscle weakness suppressing action, a muscle mass increasing action or a muscle strength increasing action, and contains a highly safe substance as an active ingredient, for suppressing muscle mass loss and for suppressing muscle weakness. , To provide a composition for increasing muscle mass or increasing muscle strength. Another object of the present invention is to provide a method for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
本発明者らは、上記課題に鑑み鋭意研究した結果、ソヤサポゲノール類及びその配糖体であるソヤサポニン類が、優れた筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を有することを見出し、この知見に基づき、本発明を完成するに至った。 As a result of diligent research in view of the above problems, the present inventors have found that soyasapogenols and their glycosides, soyasaponins, have an excellent muscle loss inhibitory effect, muscle weakness inhibitory effect, muscle mass increasing effect or muscle strength increasing effect. Based on this finding, the present invention has been completed.
すなわち、これに限定されるものではないが、本発明は以下の筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物、方法及び使用に関する。
〔1〕ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を有効成分として含む、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物。
〔2〕上記ソヤサポゲノール類の1種以上を有効成分として含む上記〔1〕に記載の組成物。
〔3〕ソヤサポゲノール類の1種以上が、ソヤサポゲノールA及び/又はソヤサポゲノールBである上記〔1〕又は〔2〕に記載の組成物。
〔4〕上記ソヤサポニン類の1種以上を有効成分として含む、上記〔1〕に記載の組成物。
〔5〕ソヤサポニン類の1種以上が、A群ソヤサポニン類及び/又はB群ソヤサポニン類の1種以上である上記〔1〕又は〔4〕に記載の組成物。
〔6〕「筋肉減少抑制」、「筋肉維持」、「筋肉増加」、「筋肉改善」、「筋力低下抑制」、「筋力維持」、「筋力増加」、「筋力改善」、「筋肉をつくる力をサポート」、「歩行機能の改善」、「歩行機能の維持」、「運動機能改善」、「運動機能維持」、「加齢によって衰える筋肉の維持」及び「加齢によって衰える筋力の維持」の1又は2以上の表示を付した、上記〔1〕〜〔5〕のいずれかに記載の組成物。That is, the present invention relates to, but is not limited to, the following compositions, methods and uses for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
[1] A composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength, which comprises one or more of soyasapogenols and / or soyasaponins as an active ingredient.
[2] The composition according to the above [1], which comprises one or more of the above soyasapogenols as an active ingredient.
[3] The composition according to the above [1] or [2], wherein one or more of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
[4] The composition according to the above [1], which comprises one or more of the above soyasaponins as an active ingredient.
[5] The composition according to the above [1] or [4], wherein one or more of the soyasaponins is one or more of the group A soyasaponins and / or the group B soyasaponins.
[6] "Muscle loss suppression", "Muscle maintenance", "Muscle gain", "Muscle improvement", "Muscle weakness suppression", "Muscle strength maintenance", "Muscle strength increase", "Muscle strength improvement", "Muscle building power""Support","Improvement of walking function", "Maintenance of walking function", "Improvement of motor function", "Maintenance of motor function", "Maintenance of muscles that decline with age" and "Maintenance of muscle strength that declines with age" The composition according to any one of the above [1] to [5], which is labeled with 1 or 2 or more.
〔7〕ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を投与することを含む、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加の方法。
〔8〕筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加のための、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上の使用。
〔9〕ソヤサポゲノール類の1種以上を投与する上記〔7〕に記載の方法。
〔10〕ソヤサポゲノール類の1種以上が、ソヤサポゲノールA及び/又はソヤサポゲノールBである上記〔7〕又は〔9〕に記載の方法。
〔11〕ソヤサポニン類の1種以上を投与する上記〔7〕に記載の方法。
〔12〕ソヤサポニン類の1種以上が、A群ソヤサポニン類及び/又はB群ソヤサポニン類の1種以上である上記〔7〕又は〔11〕に記載の方法。
〔13〕ソヤサポゲノール類の1種以上の使用である上記〔8〕に記載の使用。
〔14〕ソヤサポゲノール類の1種以上が、ソヤサポゲノールA及び/又はソヤサポゲノールBである上記〔8〕又は〔13〕に記載の使用。
〔15〕ソヤサポニン類の1種以上の使用である上記〔8〕に記載の使用。
〔16〕ソヤサポニン類の1種以上が、A群ソヤサポニン類及び/又はB群ソヤサポニン類の1種以上である上記〔8〕又は〔15〕に記載の使用。[7] A method for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength, which comprises administering one or more of soyasapogenols and / or soyasaponins.
[8] Use of one or more soyasapogenols and / or soyasaponins for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
[9] The method according to [7] above, wherein one or more of soyasapogenols are administered.
[10] The method according to the above [7] or [9], wherein one or more of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
[11] The method according to [7] above, wherein one or more of soyasaponins are administered.
[12] The method according to the above [7] or [11], wherein one or more of the soyasaponins is one or more of the group A soyasaponins and / or the group B soyasaponins.
[13] The use according to the above [8], which is the use of one or more kinds of soyasapogenols.
[14] The use according to the above [8] or [13], wherein one or more of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
[15] The use according to the above [8], which is the use of one or more kinds of soyasaponins.
[16] The use according to the above [8] or [15], wherein one or more of the soyasaponins is one or more of the group A soyasaponins and / or the group B soyasaponins.
本発明によれば、筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を有し、かつ、安全性が高い物質を有効成分として含む、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物が提供される。また本発明によれば、筋肉量減少を抑制、筋力低下を抑制、筋肉量を増加又は筋力を増加させる方法が提供される。本発明によれば、例えば、加齢等の要因による筋肉量の減少又は筋力低下を抑制して、又は、筋肉量又は筋力を増加させて、筋肉量又は筋力を維持することが可能となる。このため本発明は、高齢者等のQOLの改善に資する新たな手段を提供することができる。本発明で筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加のために使用されるソヤサポゲノール類及びソヤサポニン類は、食用植物であるダイズ等にも含まれる成分であり、安全性が高く継続的に摂取できる点でも有利である。 According to the present invention, a substance having a muscle mass loss suppressing action, a muscle weakness suppressing action, a muscle mass increasing action or a muscle strength increasing action, and containing a highly safe substance as an active ingredient, for suppressing muscle mass loss, muscle weakness Compositions for suppression, muscle mass gain or muscle strength gain are provided. Further, according to the present invention, there is provided a method of suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength. According to the present invention, for example, it is possible to maintain muscle mass or strength by suppressing a decrease in muscle mass or weakness due to factors such as aging, or by increasing muscle mass or strength. Therefore, the present invention can provide a new means that contributes to the improvement of QOL of elderly people and the like. The soyasapogenols and soyasaponins used in the present invention for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength are components contained in soybeans and the like, which are edible plants, and are highly safe and continue. It is also advantageous in that it can be ingested as a target.
本発明の筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物は、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を有効成分として含む。
本発明の組成物は、筋肉量減少抑制用組成物、筋力低下抑制用組成物、筋肉量増加用組成物又は筋力増加用組成物と表すこともできる。筋肉量又は筋力の増加は、筋肉増強ということもできる。本発明の筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物を、以下では単に本発明の組成物ともいう。The composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength of the present invention contains one or more of soyasapogenols and / or soyasaponins as an active ingredient.
The composition of the present invention can also be expressed as a composition for suppressing muscle loss, a composition for suppressing muscle weakness, a composition for increasing muscle mass, or a composition for increasing muscle strength. An increase in muscle mass or strength can also be referred to as muscle building. The composition for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength of the present invention is hereinafter simply referred to as the composition of the present invention.
ソヤサポゲノール類(ソヤサポゲノール化合物ともいうことができる)及びソヤサポニン類(ソヤサポニン化合物ということもできる)は、ダイズ(学名:Glycine max)等のマメ科植物等に含まれる化合物である。本発明の組成物には、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上として、化合物1種のみを用いてもよく、2種以上の化合物を用いてもよい。 Soyasapogenols (also referred to as soyasapogenol compounds) and soyasaponins (also referred to as soyasaponin compounds) are compounds contained in legumes such as soybean (scientific name: Glycine max). In the composition of the present invention, as one or more of soyasapogenols and / or soyasaponins, only one compound may be used, or two or more compounds may be used.
本発明におけるソヤサポゲノール類の化合物として、ソヤサポゲノールA、ソヤサポゲノールB等が挙げられる。本発明におけるソヤサポゲノール類は、これらの化合物の1種以上を含む。一態様において、本発明の組成物はソヤサポゲノール類の1種以上を有効成分として含むものであることが好ましい。筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用の観点から、ソヤサポゲノール類の1種以上として、ソヤサポゲノールA及び/又はソヤサポゲノールBが好ましい。 Examples of the soyasapogenol compounds in the present invention include soyasapogenol A and soyasapogenol B. The soyasapogenols in the present invention include one or more of these compounds. In one aspect, the composition of the present invention preferably contains one or more of soyasapogenols as an active ingredient. From the viewpoint of muscle mass loss inhibitory action, muscle weakness inhibitory action, muscle mass increasing action or muscle strength increasing action, soyasapogenol A and / or soyasapogenol B is preferable as one or more of the soyasapogenols.
ソヤサポニン類は、上記のソヤサポゲノール類をアグリコンとする配糖体である。ソヤサポニン類の化合物として、A群ソヤサポニン類、B群ソヤサポニン類等が挙げられる。A群ソヤサポニン類は、ソヤサポゲノールAをアグリコンとする配糖体である。B群ソヤサポニン類は、ソヤサポゲノールBをアグリコンとする配糖体である。ソヤサポゲノール類は、化合物1種以上を含む。本発明の組成物はソヤサポニン類の1種以上を有効成分として含むものであってよい。筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用の観点から、ソヤサポニン類の1種以上として、A群ソヤサポニン類及び/又はB群ソヤサポニン類の1種以上が好ましい。 Soyasaponins are glycosides containing the above-mentioned soyasapogenols as aglycones. Examples of the compound of soyasaponins include group A soyasaponins and group B soyasaponins. Group A soyasaponins are glycosides containing soyasapogenol A as an aglycone. Group B soyasaponins are glycosides containing soyasapogenol B as an aglycone. Soyasapogenols include one or more compounds. The composition of the present invention may contain one or more of soyasaponins as an active ingredient. From the viewpoint of muscle mass loss suppressing action, muscle weakness suppressing action, muscle mass increasing action or muscle strength increasing action, one or more of group A soyasaponins and / or group B soyasaponins are preferable as one or more of soyasaponins.
A群ソヤサポニン類の例として、ソヤサポニンAa(ソヤサポニンA4)、ソヤサポニンAb(ソヤサポニンA1)、ソヤサポニンAc、ソヤサポニンAd、ソヤサポニンAe(ソヤサポニンA5)、ソヤサポニンAf(ソヤサポニンA2)、ソヤサポニンAg(ソヤサポニンA6)、ソヤサポニンAh(ソヤサポニンA3)が挙げられる。中でも、ソヤサポニンAa、ソヤサポニンAbが好ましい。 Examples of group A soyasaponins are soyasaponin Aa (soyasaponin A4), soyasaponin Ab (soyasaponin A1), soyasaponin Ac, soyasaponin Ad, soyasaponin Ae (soyasaponin A5), soyasaponin Af (soyasaponin A5), soyasaponin Af (soyasaponin A2) Ah (Soyasaponin A3) can be mentioned. Of these, soyasaponin Aa and soyasaponin Ab are preferable.
B群ソヤサポニン類の例として、ソヤサポニンBa(ソヤサポニンV)、ソヤサポニンBb(ソヤサポニンI)、ソヤサポニンBc(ソヤサポニンII)、ソヤサポニンBb’(ソヤサポニンIII)、ソヤサポニンBc’(ソヤサポニンIV)が挙げられる。中でも、ソヤサポニンBa、ソヤサポニンBbが好ましい。 Examples of group B soyasaponins include soyasaponin Ba (soyasaponin V), soyasaponin Bb (soyasaponin I), soyasaponin Bc (soyasaponin II), soyasaponin Bb'(soyasaponin III), and soyasaponin Bc'(soyasaponin IV). Of these, soyasaponin Ba and soyasaponin Bb are preferable.
一態様において、ソヤサポゲノール類及び/又はソヤサポニン類として、ソヤサポゲノール類が好ましく、ソヤサポゲノールA及び/又はソヤサポゲノールBがより好ましい。 In one aspect, as soyasapogenols and / or soyasaponins, soyasapogenols are preferable, and soyasapogenol A and / or soyasapogenol B is more preferable.
ソヤサポゲノール類及び/又はソヤサポニン類を得るための由来、製法については特に制限はない。ソヤサポゲノール類及び/又はソヤサポニン類を多く含む植物又はその部位として、ダイズ(特にダイズ種子(大豆))、小豆、葛根などが知られている。これらの植物から、公知の方法でソヤサポゲノール類及び/又はソヤサポニン類を抽出及び精製して調製することができる。ソヤサポゲノール類は、ソヤサポニン類を公知の方法で加水分解することによって得ることもできる。ソヤサポゲノール類及びソヤサポニン類は、市販品を使用することもできる。 There are no particular restrictions on the origin and manufacturing method for obtaining soyasapogenols and / or soyasaponins. Soybeans (particularly soybean seeds (soybeans)), adzuki beans, kakkonto, etc. are known as plants or parts thereof containing a large amount of soyasapogenols and / or soyasaponins. From these plants, soyasapogenols and / or soyasaponins can be extracted and purified and prepared by a known method. Soyasapogenols can also be obtained by hydrolyzing soyasaponins by a known method. Commercially available products can also be used for soyasapogenols and soyasaponins.
本発明においては、本発明の効果を奏することになる限り、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を豊富に含む植物由来原料を本発明の組成物に含有させてもよい。ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を豊富に含む植物由来原料としては、例えば、ダイズ種子を生のまま又は凍結乾燥などによって乾燥させたもの、ダイズ種子を熱水又は有機溶剤により抽出した液(抽出液)を濃縮又は凍結乾燥したもの、又は、抽出液の乾燥物をカラム等で精製し、ソヤサポゲノール類及び/又はソヤサポニン類を高純度化したもの等を使用することができる。このようなソヤサポゲノール類及び/又はソヤサポニン類の1種以上を含む植物由来原料は、市販のものを使用してもよく、ダイズ等の植物から公知の方法で調製してもよい。 In the present invention, a plant-derived raw material rich in one or more of soyasapogenols and / or soyasaponins may be contained in the composition of the present invention as long as the effects of the present invention are exhibited. Examples of plant-derived raw materials rich in one or more of soyasapogenols and / or soyasaponins include soybean seeds raw or dried by freeze-drying, and soybean seeds extracted with hot water or an organic solvent. A concentrated or freeze-dried solution (extract), or a highly purified soyasapogenol and / or soyasaponins obtained by purifying the dried extract with a column or the like can be used. As the plant-derived raw material containing one or more of such soyasapogenols and / or soyasaponins, a commercially available one may be used, or a plant such as soybean may be prepared by a known method.
実施例に示されるように、ソヤサポゲノール類又はソヤサポニン類を老齢マウスに摂取させると、当該マウスの握力が増加した。また、ソヤサポゲノール類又はソヤサポニン類の摂取により、老齢マウスの体重あたりの筋肉重量の割合が増加した。また、絶食によってタンパク質合成量が減少するところ、ソヤサポゲノール類を摂取させたマウスでは、絶食群と比較して有意に筋タンパク質合成量が増加した。ソヤサポゲノール類を摂取させたマウスでは、p70S6キナーゼ(p70S6K)のリン酸化も促進された。p70S6Kは、筋タンパク質合成を制御する主要因子であり、リン酸化されると筋タンパク質合成が促進される。従ってp70S6Kのリン酸化の促進は、筋タンパク質の合成を促進し、筋肉量の減少抑制又は増加をもたらす。筋タンパク質の合成促進による筋肉量の減少抑制又は増加により、筋力の低下抑制又は増加効果が得られる。
また、ソヤサポゲノール類の1種以上を摂取させたマウスでは、オレアノール酸及びマスリン酸を摂取させたマウスよりも筋タンパク質合成量が多かった。このことは、ソヤサポゲノール類がオレアノール酸及びマスリン酸よりも優れた筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を示すことを意味する。さらに、実施例に示されるように、ソヤサポゲノール類を含む画分は、筋芽細胞から筋管細胞へ分化を促進した。筋肉は、筋芽細胞が筋管細胞へ分化し、さらに筋管細胞が融合した筋線維から形成されている。筋芽細胞から筋管細胞への分化が促進されることは、筋肉量の減少抑制又は増加をもたらし、筋力の低下抑制又は増加をもたらす。なおソヤサポニン類についても、摂取されたソヤサポニン類は、体内で、消化酵素又は代謝酵素の働きによりソヤサポゲノール類となり、体内でソヤサポゲノール類と同様の効果を発揮すると考えられる。
従ってソヤサポゲノール類及び/又はソヤサポニン類は、筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用又は筋力増加作用を有し、筋肉量減少を抑制するため、筋力低下を抑制するため、筋肉量を増加させるため又は筋力を増加させるために使用され得る。またソヤサポゲノール類及び/又はソヤサポニン類は、p70S6キナーゼのリン酸化促進のため、筋芽細胞から筋管細胞への分化促進のためにも使用され得る。As shown in the examples, when soyasapogenols or soyasaponins were ingested by aged mice, the grip strength of the mice was increased. Ingestion of soyasapogenols or soyasaponins also increased the proportion of muscle weight per body weight of aged mice. In addition, while the amount of protein synthesis decreased due to fasting, the amount of muscle protein synthesis increased significantly in the mice fed with soyasapogenols as compared with the fasted group. Phosphorylation of p70S6 kinase (p70S6K) was also promoted in mice fed with soyasapogenols. p70S6K is a major factor that controls muscle protein synthesis, and when phosphorylated, muscle protein synthesis is promoted. Therefore, promotion of phosphorylation of p70S6K promotes muscle protein synthesis and suppresses or increases muscle mass loss. By suppressing or increasing the decrease or increase in muscle mass by promoting the synthesis of muscle protein, the effect of suppressing or increasing the decrease in muscle strength can be obtained.
In addition, the amount of muscle protein synthesis was higher in the mice fed with one or more of soyasapogenols than in the mice fed with oleanolic acid and maslinic acid. This means that soyasapogenols exhibit a muscle loss inhibitory effect, a muscle weakness inhibitory effect, a muscle mass increasing effect or a muscle strength increasing effect, which are superior to those of oleanolic acid and maslinic acid. Furthermore, as shown in the examples, the fraction containing soyasapogenols promoted the differentiation from myoblasts to myotube cells. Muscle is formed from muscle fibers in which myoblasts differentiate into myotube cells and further myotube cells are fused. The promotion of differentiation of myoblasts into myotube cells results in suppression or increase in muscle mass, and suppression or increase in muscle strength. As for soyasaponins, the ingested soyasaponins become soyasapogenols by the action of digestive enzymes or metabolic enzymes in the body, and it is considered that the ingested soyasaponins exert the same effect as soyasapogenols in the body.
Therefore, soyasapogenols and / or soyasaponins have a muscle mass loss suppressing action, a muscle weakness suppressing action, a muscle mass increasing action or a muscle strength increasing action, and suppress the muscle mass loss, thus suppressing the muscle weakness, and thus the muscle mass. Can be used to increase muscle strength. Soyasapogenols and / or soyasaponins can also be used to promote the phosphorylation of p70S6 kinase and to promote the differentiation of myoblasts into myotube cells.
本発明の組成物は、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を有効成分として含むことにより、優れた筋肉量減少抑制効果、筋力低下抑制効果、筋肉量増加効果又は筋力増加効果を奏する。また、このような効果により、例えば、筋肉量減少の予防、筋肉量の維持、筋力低下の予防、筋力維持、筋肉量が減少した状態又は筋力が低下した状態の改善等が可能となる。従って本発明の組成物は、筋肉量の減少予防のため、筋力低下予防のため、筋肉量が減少した状態の改善のため、筋力が低下した状態の改善のため、筋肉量維持のため、筋力維持のため等に使用され得る。一態様において、本発明の組成物は、筋肉量の減少抑制又は筋力低下抑制のために好適に使用され、例えば、加齢による筋委縮等による筋肉量減少の抑制、筋力低下抑制等のために好適に使用され得る。筋肉としては、骨格筋が好ましく、脚等の筋肉が挙げられる。筋肉量の増加は、体重あたりの筋肉重量の増加であり得る。
ヒト等の動物の筋肉量は、例えば、マイクロPET/CT(陽電子(ポジトロン)放射断層撮影/コンピュータ断層撮影、INVEON、シーメンス、米国)により測定することができる。The composition of the present invention exhibits an excellent muscle mass loss suppressing effect, muscle weakness suppressing effect, muscle mass increasing effect or muscle strength increasing effect by containing one or more of soyasapogenols and / or soyasaponins as an active ingredient. Further, such an effect enables, for example, prevention of muscle mass loss, maintenance of muscle mass, prevention of muscle weakness, maintenance of muscle strength, improvement of a state of reduced muscle mass or a state of reduced muscle strength, and the like. Therefore, the composition of the present invention is used for preventing muscle mass loss, preventing muscle weakness, improving a state of muscle weakness, improving a state of muscle weakness, maintaining muscle mass, and maintaining muscle strength. It can be used for maintenance, etc. In one aspect, the composition of the present invention is suitably used for suppressing muscle mass loss or muscle weakness, for example, for suppressing muscle loss due to aging-related muscle atrophy, suppressing muscle weakness, and the like. It can be preferably used. As the muscle, skeletal muscle is preferable, and muscles such as legs can be mentioned. An increase in muscle mass can be an increase in muscle weight per body weight.
The muscle mass of animals such as humans can be measured by, for example, micro PET / CT (positron emission tomography / computed tomography, INVEON, Siemens, USA).
本発明の組成物は、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加により予防又は改善が期待できる状態又は疾患の処置のために用いることができる。このような状態又は疾患として、例えば、ロコモティブシンドローム、カヘキシア(がんや慢性疾患などの消耗性疾患が原因となり、食欲不振と代謝調節機構の障害による重度の骨格筋の萎縮と臓器の機能不全の病態を示す状態)等の筋肉量が減少した又は筋力が低下した状態又は疾患が挙げられる。
本明細書で状態又は疾患の予防は、状態又は疾患の発症を防止すること、状態又は疾患の発症を遅延させること、状態又は疾患の発症率を低下させること、状態又は疾患の発症のリスクを軽減することを包含する。状態又は疾患の改善は、対象を状態又は疾患から回復させること、状態又は疾患の症状を軽減すること、状態又は疾患の進行を遅延させること又は防止することを包含する。The composition of the present invention can be used for the treatment of a condition or disease in which prevention or improvement can be expected by suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength. Such conditions or diseases include, for example, locomotive syndrome, cahexia (caused by debilitating diseases such as cancer and chronic diseases, severe skeletal muscle atrophy and organ dysfunction due to loss of appetite and impaired metabolic regulation). Examples include a state in which muscle mass is reduced or muscle strength is weakened, such as a state indicating a pathological condition, or a disease.
As used herein, prevention of a condition or disease involves preventing the onset of the condition or disease, delaying the onset of the condition or disease, reducing the incidence of the condition or disease, or risking the development of the condition or disease. Including mitigation. Improvement of a condition or disease includes recovering the subject from the condition or disease, alleviating the symptoms of the condition or disease, delaying or preventing the progression of the condition or disease.
本発明の組成物は、治療用途(医療用途)又は非治療用途(非医療用途)のいずれにも適用することができる。
本発明の組成物は、例えば、飲食品、医薬品、医薬部外品、飼料等の形態で提供することができるが、これらに限定されるものではない。本発明の組成物は、それ自体が飲食品、医薬品、医薬部外品、飼料等であってもよく、これらに使用される添加剤等の製剤、素材であってもよい。本発明の組成物は、一例として、剤の形態で提供することができるが、本形態に限定されるものではない。当該剤をそのまま組成物として、又は、当該剤を含む組成物として提供することもできる。本発明の組成物は、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加のための剤ということもできる。
一態様において、本発明の組成物は、好ましくは経口用組成物である。本発明によれば、優れた筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加作用を有する経口用組成物を提供することができる。経口用組成物として、飲食品、医薬品、医薬部外品が挙げられ、好ましくは飲食品である。The composition of the present invention can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use).
The composition of the present invention can be provided, for example, in the form of foods and drinks, pharmaceuticals, quasi-drugs, feeds, etc., but is not limited thereto. The composition of the present invention may itself be a food or drink, a pharmaceutical product, a quasi-drug, a feed, or the like, or may be a preparation or a material of an additive or the like used for these. The composition of the present invention can be provided, for example, in the form of an agent, but is not limited to this form. The agent can be provided as it is as a composition or as a composition containing the agent. The composition of the present invention can also be said to be an agent for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
In one aspect, the composition of the invention is preferably an oral composition. According to the present invention, it is possible to provide an oral composition having an excellent effect of suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength. Examples of the oral composition include foods and drinks, pharmaceuticals, and quasi-drugs, and foods and drinks are preferable.
本発明の組成物は、本発明の効果を損なわない限り、上述したソヤサポゲノール類及び/又はソヤサポニン類以外に、任意の添加剤、任意の成分を含有することができる。これらの添加剤及び成分は、組成物の形態等に応じて選択することができ、一般的に飲食品、医薬品、医薬部外品、飼料等に使用可能なものが使用できる。 The composition of the present invention may contain any additive and any component in addition to the above-mentioned soyasapogenols and / or soyasaponins as long as the effects of the present invention are not impaired. These additives and ingredients can be selected according to the form of the composition and the like, and generally those that can be used for foods and drinks, pharmaceuticals, quasi-drugs, feeds and the like can be used.
本発明の組成物を飲食品とする場合、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上に、飲食品に使用可能な成分(例えば、飲食品素材、必要に応じて使用される添加剤等)を配合して、種々の飲食品とすることができる。飲食品は特に限定されず、例えば、一般的な飲食品、健康食品、食品添加剤、これらの原料等が挙げられる。飲食品の形態も特に限定されず、固形状、半流動状、流動状などを挙げることができる。飲食品は、錠剤、被覆錠剤、細粒剤、顆粒剤、散剤、丸薬、カプセル剤、ドライシロップ剤、チュアブル剤等の経口用固形製剤;内服液剤、シロップ剤等の経口用液体製剤の各種製剤形態とすることもできる。 When the composition of the present invention is used as a food or drink, one or more of soyasapogenols and / or soyasaponins and components that can be used in the food and drink (for example, food and drink materials, additives used as necessary, etc.) Can be blended into various foods and drinks. Foods and drinks are not particularly limited, and examples thereof include general foods and drinks, health foods, food additives, and raw materials thereof. The form of the food or drink is not particularly limited, and examples thereof include solid, semi-fluid, and fluid. Foods and drinks are oral solid preparations such as tablets, coated tablets, fine granules, granules, powders, pills, capsules, dry syrups and chewables; various forms of oral liquid preparations such as oral liquids and syrups. It can also be.
本発明の組成物を医薬品又は医薬部外品とする場合、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上に、薬理学的に許容される賦形剤等を配合して、各種剤形の医薬品とすることができる。本発明の効果をより充分に得る観点から、医薬品又は医薬部外品の投与形態は、経口投与が好ましい。剤形は、投与形態に適した剤形とすればよい。経口用医薬品の剤形として、例えば、錠剤、被覆錠剤、細粒剤、顆粒剤、散剤、丸薬、カプセル剤、ドライシロップ剤、チュアブル剤等の経口用固形製剤;内服液剤、シロップ剤等の経口用液体製剤が挙げられる。医薬品は、非ヒト動物用医薬であってもよい。 When the composition of the present invention is a pharmaceutical product or a quasi-drug, a pharmaceutical product in various dosage forms is prepared by blending one or more of soyasapogenols and / or soyasaponins with a pharmacologically acceptable excipient or the like. Can be. From the viewpoint of more fully obtaining the effects of the present invention, oral administration is preferable as the administration form of the drug or quasi-drug. The dosage form may be a dosage form suitable for the dosage form. Dosage forms of oral pharmaceuticals include, for example, oral solid preparations such as tablets, coated tablets, fine granules, granules, powders, pills, capsules, dry syrups, chewables; oral solutions such as oral solutions and syrups. Examples include liquid formulations. The drug may be a non-human veterinary drug.
本発明の組成物を飼料とする場合、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上に、飼料に使用可能な成分を配合して飼料とすることができる。飼料としては、例えば、ウシ、ブタ、ニワトリ、ヒツジ、ウマ等に用いる家畜用飼料;ウサギ、モルモット、ラット、マウス等に用いる小動物用飼料;イヌ、ネコ、小鳥等に用いるペットフードなどが挙げられる。 When the composition of the present invention is used as a feed, one or more of soyasapogenols and / or soyasaponins can be mixed with components that can be used in the feed to make a feed. Examples of the feed include livestock feed used for cattle, pigs, chickens, sheep, horses, etc .; small animal feed used for rabbits, guinea pigs, rats, mice, etc .; pet food used for dogs, cats, small birds, etc. ..
本発明の組成物を、飲食品、医薬品、医薬部外品、飼料等とする場合、その製造方法は特に限定されず、有効成分として使用されるソヤサポゲノール類及び/又はソヤサポニン類の1種以上を用いて、一般的な方法により製造することができる。
本発明の組成物の製造においては、ソヤサポゲノール類及び/又はソヤサポニン類として、精製された化合物を使用してもよく、上述したソヤサポゲノール類及び/又はソヤサポニン類の1種以上を豊富に含む植物由来原料を使用してもよい。ソヤサポゲノール類及び/又はソヤサポニン類は、当該化合物を含む植物由来原料の形態で組成物に含有させてもよい。When the composition of the present invention is a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc., the production method thereof is not particularly limited, and one or more of soyasapogenols and / or soyasaponins used as active ingredients may be used. It can be produced by a general method.
In the production of the composition of the present invention, purified compounds may be used as soyasapogenols and / or soyasaponins, and a plant-derived raw material rich in one or more of the above-mentioned soyasapogenols and / or soyasaponins. May be used. Soyasapogenols and / or soyasaponins may be included in the composition in the form of plant-derived ingredients containing the compound.
本発明の組成物には、包装、容器又は説明書等に用途、有効成分の種類、上述した効果、使用方法(例えば、摂取方法、投与方法)等の1又は2以上を表示してもよい。本発明の組成物には、筋肉量減少抑制作用、筋力低下抑制作用、筋肉量増加作用若しくは筋力増加作用、又は、これらの作用に基づく作用を有する旨の表示が付されていてもよい。本発明の組成物には、例えば、「筋肉減少抑制」、「筋肉維持」、「筋肉増加」、「筋肉改善」、「筋力低下抑制」、「筋力維持」、「筋力増加」、「筋力改善」、「筋肉をつくる力をサポート」、「歩行機能の改善」、「歩行機能の維持」、「運動機能改善」、「運動機能維持」、「加齢によって衰える筋肉の維持」及び「加齢によって衰える筋力の維持」等の1又は2以上の表示が付されていてもよい。 The composition of the present invention may indicate one or more of the intended use, the type of active ingredient, the above-mentioned effect, the method of use (for example, ingestion method, administration method), etc. on the packaging, container, instruction manual, or the like. .. The composition of the present invention may be labeled as having a muscle mass loss suppressing action, a muscle weakness suppressing action, a muscle mass increasing action or a muscle strength increasing action, or an action based on these actions. The composition of the present invention includes, for example, "muscle loss suppression", "muscle maintenance", "muscle gain", "muscle improvement", "muscle weakness suppression", "muscle strength maintenance", "muscle strength increase", "muscle strength improvement". , "Supporting the ability to build muscle", "Improvement of walking function", "Maintenance of walking function", "Improvement of motor function", "Maintenance of motor function", "Maintenance of muscles that decline with age" and "Aging" One or two or more indications such as "maintenance of muscular strength weakened by" may be attached.
本発明の組成物中のソヤサポゲノール類及び/又はソヤサポニン類の含有量は、該組成物の形態等に応じて適宜設定することができる。例えば、ソヤサポゲノール類及びソヤサポニン類の総含有量は、組成物中に0.01〜90重量%であってよい。一態様において、本発明の組成物を、飲食品、医薬品、医薬部外品等の経口用組成物とする場合、ソヤサポゲノール類及びソヤサポニン類の総含有量は、組成物中に0.01重量%以上が好ましく、0.2重量%以上がより好ましく、また、20重量%以下が好ましく、10重量%以下がより好ましい。一態様において、ソヤサポゲノール類及びソヤサポニン類の総含有量は、本発明の組成物中に0.01〜20重量%が好ましく、0.2〜10重量%がより好ましい。上記総含有量は、ソヤサポゲノール類及び/又はソヤサポニン類の化合物が2種以上含まれる場合、それらの合計量である。ソヤサポゲノール類及び/又はソヤサポニン類の含有量は、公知の方法に従って測定することができ、例えば、HPLC法等を用いることができる。 The content of soyasapogenols and / or soyasaponins in the composition of the present invention can be appropriately set according to the form of the composition and the like. For example, the total content of soyasapogenols and soyasaponins may be 0.01-90% by weight in the composition. In one embodiment, when the composition of the present invention is used as an oral composition for foods and drinks, pharmaceuticals, quasi-drugs, etc., the total content of soyasapogenols and soyasaponins is 0.01% by weight in the composition. The above is preferable, 0.2% by weight or more is more preferable, 20% by weight or less is preferable, and 10% by weight or less is more preferable. In one aspect, the total content of soyasapogenols and soyasaponins is preferably 0.01 to 20% by weight, more preferably 0.2 to 10% by weight in the composition of the present invention. The total content is the total amount of soyasapogenols and / or soyasaponins when two or more compounds are contained. The content of soyasapogenols and / or soyasaponins can be measured according to a known method, and for example, an HPLC method or the like can be used.
本発明の組成物は、その形態に応じた適当な方法で摂取又は投与することができる。本発明の組成物は、好ましくは、経口投与又は経口摂取される。
本発明の組成物の摂取量(投与量ということもできる)は特に限定されず、筋肉量減少抑制効果、筋力低下抑制効果、筋肉量増加効果又は筋力増加効果が得られるような量(有効量)であればよく、投与形態、投与方法等に応じて適宜設定すればよい。例えば、ヒト(成人)を対象に経口で投与する又は摂取させる場合、ソヤサポゲノール類及びソヤサポニン類の総摂取量は、1日あたり、5mg以上が好ましく、10mg以上がより好ましく、20mg以上がさらに好ましく、また、500mg以下が好ましく、200mg以下がより好ましく、100mg以下がさらに好ましい。一態様として、ヒト(成人)を対象に経口で投与する又は摂取させる場合、本発明の組成物の摂取量は、ソヤサポゲノール類及びソヤサポニン類の総摂取量として、1日あたり、5〜500mgが好ましく、10〜200mgがより好ましく、20〜100mgがさらに好ましい。上記量を、例えば1日1回で又は2〜3回に分けて経口投与又は摂取させることが好ましい。ヒト(成人)を対象に筋肉量減少抑制効果、筋力低下抑制効果、筋肉量増加効果又は筋力増加効果を得ることを目的として本発明の組成物を摂取させる場合は、ソヤサポゲノール類及びソヤサポニン類の総摂取量が上記範囲となるように、本発明の組成物を対象に経口で摂取させる又は投与することが好ましい。The composition of the present invention can be ingested or administered by an appropriate method according to its form. The compositions of the present invention are preferably orally administered or orally ingested.
The intake amount (which can also be referred to as a dose) of the composition of the present invention is not particularly limited, and an amount (effective amount) capable of obtaining a muscle mass loss suppressing effect, a muscle weakness suppressing effect, a muscle mass increasing effect, or a muscle strength increasing effect. ), And may be appropriately set according to the administration form, administration method, and the like. For example, when a human (adult) is orally administered or ingested, the total intake of soyasapogenols and soyasaponins is preferably 5 mg or more, more preferably 10 mg or more, still more preferably 20 mg or more per day. Further, 500 mg or less is preferable, 200 mg or less is more preferable, and 100 mg or less is further preferable. In one aspect, when a human (adult) is orally administered or ingested, the intake of the composition of the present invention is preferably 5 to 500 mg per day as the total intake of soyasapogenols and soyasaponins. , 10 to 200 mg is more preferable, and 20 to 100 mg is even more preferable. It is preferable that the above amount is orally administered or ingested, for example, once a day or divided into 2 to 3 times. When the composition of the present invention is ingested for the purpose of obtaining a muscle mass loss suppressing effect, a muscle weakness suppressing effect, a muscle mass increasing effect or a muscle strength increasing effect in a human (adult), the total of soyasapogenols and soyasaponins It is preferable that the composition of the present invention is orally ingested or administered to the subject so that the intake amount is within the above range.
一態様において、本発明の組成物は、その投与形態、投与方法等を考慮して、本発明の所望の効果が得られるような量、すなわち有効量の上記ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を含有することが好ましい。一態様として例えば、本発明の組成物が飲食品、経口用医薬品等の経口用組成物である場合、該組成物の成人1人1日当たりの摂取量中に、ソヤサポゲノール類及びソヤサポニン類の総含有量が、5〜500mgが好ましく、10〜200mgがより好ましく、20〜100mgがさらに好ましい。 In one aspect, the composition of the present invention is one of the above-mentioned soyasapogenols and / or soyasaponins in an amount such that the desired effect of the present invention can be obtained in consideration of its administration form, administration method and the like. It preferably contains more than a seed. As one embodiment, for example, when the composition of the present invention is an oral composition such as a food or drink, an oral drug, etc., the total content of soyasapogenols and soyasaponins in the daily intake of the composition per adult. The amount is preferably 5 to 500 mg, more preferably 10 to 200 mg, still more preferably 20 to 100 mg.
ソヤサポゲノール類及び/又はソヤサポニン類は、継続的に摂取(投与)されることによって、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加効果が高まることが期待される。好ましい態様において、本発明の組成物は、継続して摂取されるものである。本発明の一実施態様において、本発明の組成物は、好ましくは1週間以上、より好ましくは4週間以上、さらに好ましくは8週間以上継続して摂取されることが好ましい。 By continuously ingesting (administering) soyasapogenols and / or soyasaponins, it is expected that the effects of suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength are enhanced. In a preferred embodiment, the compositions of the invention are for continuous ingestion. In one embodiment of the present invention, the composition of the present invention is preferably continuously ingested for 1 week or longer, more preferably 4 weeks or longer, still more preferably 8 weeks or longer.
本発明の組成物を投与又は摂取させる対象(以下、単に投与対象ともいう)は、哺乳動物(ヒト及び非ヒト哺乳動物)が好ましく、ヒトがより好ましい。また、本発明における投与対象として、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加を必要とする又は希望する対象が好ましい。例えば、筋肉量が減少した対象、筋力が低下した対象、上述した筋肉量が減少した又は筋力が低下した状態又は疾患の予防又は改善を希望する対象等が好適な対象として挙げられる。一態様において、本発明の組成物の投与対象は、高齢者が好ましい。ソヤサポゲノール類及び/又はソヤサポニン類は、例えば、高齢者における筋肉量減少(加齢による筋肉量減少)の抑制、筋力低下(加齢による筋力低下)の抑制のために好適に使用される。一態様において、本発明の組成物は、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加により改善が期待できる状態又は疾患の予防を目的として、健常な状態にある対象に対して用いることができる。 Mammals (humans and non-human mammals) are preferable, and humans are more preferable, as the subject to which the composition of the present invention is administered or ingested (hereinafter, also simply referred to as an administration subject). In addition, as the administration target in the present invention, a target that requires or desires suppression of muscle loss, suppression of muscle weakness, increase in muscle mass, or increase in muscle strength is preferable. For example, a subject having a decreased muscle mass, a subject having a decreased muscle strength, a subject having a decreased muscle mass or a decreased muscle strength described above, or a subject who desires prevention or improvement of a disease can be mentioned as suitable subjects. In one aspect, the subject of administration of the composition of the present invention is preferably an elderly person. Soyasapogenols and / or soyasaponins are suitably used for suppressing muscle weakness (muscle loss due to aging) and muscle weakness (muscle weakness due to aging) in the elderly, for example. In one aspect, the composition of the present invention is used for a healthy subject for the purpose of suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or preventing a condition or disease that can be expected to be improved by increasing muscle mass or strength. be able to.
本発明は、以下の筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加方法も包含する。
ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を投与することを含む、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加の方法。
上記方法は、治療的な方法であってもよく、非治療的な方法であってもよい。「非治療的」とは、医療行為、すなわち手術、治療又は診断を含まない概念である。
ソヤサポゲノール類及び/又はソヤサポニン類の投与量は、筋肉量減少抑制効果、筋力低下抑制効果、筋肉量増加効果又は筋力増加効果が得られる量、すなわち有効量であればよく、特に限定されず、例えば上述した量を投与することが好ましい。ソヤサポゲノール類及び/又はソヤサポニン類は、そのまま投与してもよいし、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を含有する組成物として投与してもよい。例えば、上述した本発明の組成物を投与することができる。ソヤサポゲノール類及び/又はソヤサポニン類、投与対象、投与方法、投与量及びそれらの好ましい態様等は、上述した本発明の組成物におけるものと同じである。本発明によれば、副作用を生じず安全に、優れた筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加効果を得ることができる。The present invention also includes the following methods of suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
A method of suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength, which comprises administering one or more of soyasapogenols and / or soyasaponins.
The above method may be a therapeutic method or a non-therapeutic method. "Non-therapeutic" is a concept that does not include medical practice, ie surgery, treatment or diagnosis.
The dose of soyasapogenols and / or soyasaponins may be an amount that can obtain a muscle loss suppressing effect, a muscle weakness suppressing effect, a muscle mass increasing effect or a muscle strength increasing effect, that is, an effective amount, and is not particularly limited, for example. It is preferable to administer the amount described above. Soyasapogenols and / or soyasaponins may be administered as they are, or may be administered as a composition containing one or more of soyasapogenols and / or soyasaponins. For example, the composition of the present invention described above can be administered. The soyasapogenols and / or soyasaponins, the subject to be administered, the method of administration, the dose and preferred embodiments thereof are the same as those in the composition of the present invention described above. According to the present invention, it is possible to safely obtain excellent effects of suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength without causing side effects.
本発明は、筋肉量減少抑制、筋力低下抑制、筋肉量増加又は筋力増加のための、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上の使用、も包含する。
上記の使用は、通常、ヒト又は非ヒト動物における使用であり、好ましくはヒト又は非ヒト哺乳動物、さらに好ましくはヒトにおける使用である。使用は、治療的使用であってもよく、非治療的使用であってもよい。ソヤサポゲノール類及び/又はソヤサポニン類等の好ましい態様等は、上述した本発明の組成物と同じである。The present invention also includes the use of one or more soyasapogenols and / or soyasaponins for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength.
The above uses are usually in humans or non-human animals, preferably in humans or non-human mammals, more preferably in humans. The use may be therapeutic or non-therapeutic use. Preferred embodiments of soyasapogenols and / or soyasaponins and the like are the same as those of the composition of the present invention described above.
本発明の方法及び使用において、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上として、1種の化合物を用いてもよく、2種以上の化合物を用いてもよい。上記の方法及び使用においては、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を継続して投与することが好ましい。一態様において、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上を、好ましくは1週間以上、より好ましくは4週間以上、さらに好ましくは8週間以上継続して投与することが好ましい。 In the method and use of the present invention, one kind of compound may be used as one or more kinds of soyasapogenols and / or soyasaponins, or two or more kinds of compounds may be used. In the above method and use, it is preferable to continuously administer one or more of soyasapogenols and / or soyasaponins. In one embodiment, it is preferable to continuously administer one or more of soyasapogenols and / or soyasaponins for preferably 1 week or longer, more preferably 4 weeks or longer, still more preferably 8 weeks or longer.
本発明は一態様において、筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物を製造するための、ソヤサポゲノール類及び/又はソヤサポニン類の1種以上の使用も包含する。ソヤサポゲノール類及び/又はソヤサポニン類や筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物及びその好ましい態様等は、上記の本発明の組成物及びその好ましい態様と同じである。 In one aspect, the present invention also includes the use of one or more soyasapogenols and / or soyasaponins for producing compositions for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength. To do. Soyasapogenols and / or soyasaponins, compositions for suppressing muscle loss, suppressing muscle weakness, increasing muscle mass or increasing muscle strength, and preferred embodiments thereof are the same as the compositions of the present invention and preferred embodiments thereof. Is.
以下、本発明を実施例によりさらに詳しく説明するが、これにより本発明の範囲を限定するものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but this does not limit the scope of the present invention.
なお、実施例及び比較例を含めた動物実験は全て、動物愛護管理法他関連法令を遵守し、社内動物実験委員会の審査を経て機関の長が承認した計画に基づき実施した。 All animal experiments, including examples and comparative examples, were conducted based on a plan approved by the head of the institution after being examined by the in-house animal experiment committee in compliance with the Animal Care Management Law and other related laws and regulations.
<調製例1>
ソヤサポニンの入手方法及びソヤサポゲノール粗画分の調製法
以下の試験では、ソヤサポニンとして、市販の大豆由来サポニン(株式会社J−オイルミルズ製のサポニンB−50(B群大豆サポニン含量が60重量%、A群大豆サポニン含量が13重量%))を用いて評価した。サポニンB−50中のB群大豆サポニンには、ソヤサポニンBa、ソヤサポニンBb等が含まれ、A群大豆サポニンにはソヤサポニンAa、ソヤサポニンAb等が含まれる。
大豆由来サポゲノールを含む画分は、次の方法で調製した。サポニンB−50を20倍量、2規定の塩酸水溶液にて100℃で2時間反応させ、サポニンの糖鎖を切断した。反応終了後、反応液を室温まで冷却し、水酸化ナトリウム水溶液にて中和した。その反応液を吸引濾過し、残渣について大量の蒸留水で洗浄、吸引濾過を繰り返し、水酸化ナトリウムの残存がないことを確認し、乾燥し、ソヤサポゲノール粗画分(純度50%:ソヤサポゲノールA及びBの合計)を得た。<Preparation Example 1>
How to obtain soyasaponin and how to prepare the coarse fraction of soyasapogenol In the following tests, commercially available soybean-derived saponin (Saponin B-50 manufactured by J-Oil Mills Co., Ltd. (Group B soybean saponin content is 60% by weight, A) The group soybean saponin content was 13% by weight)). Group B soybean saponin in saponin B-50 includes soybean saponin Ba, soybean saponin Bb and the like, and group A soybean saponin includes soybean saponin Aa, soybean saponin Ab and the like.
Fractions containing soybean-derived sapogenol were prepared by the following method. A 20-fold amount of saponin B-50 was reacted in a 2N hydrochloric acid aqueous solution at 100 ° C. for 2 hours to cleave the sugar chain of saponin. After completion of the reaction, the reaction solution was cooled to room temperature and neutralized with an aqueous sodium hydroxide solution. The reaction solution is suction-filtered, the residue is washed with a large amount of distilled water, suction filtration is repeated, it is confirmed that there is no residual sodium hydroxide, and the residue is dried. Total) was obtained.
<試験例1>
C57BL/6J雄性マウスの加齢による筋力の低下
C57BL/6J雄性マウス(日本チャールスリバー株式会社)の筋力の加齢変化を確認するために、指標となる四肢握力合計値の推移を検証した。7ヶ月齢(23匹)、20ヶ月齢(22匹)、22ヶ月齢(7匹)及び24ヶ月齢(7匹)時点の四肢握力合計値を、握力測定機器(MK−380S、室町機械株式会社)を用いて測定し、握力とした。有意差検定にはDunnettの多重比較検定を用いた。7ヶ月齢(7M)、20ヶ月齢(20M)、22ヶ月齢(22M)及び24ヶ月齢(24M)の各群の握力測定結果を図1に示す(*:P<0.05、**:P<0.01、7ヶ月齢との比較)。結果は、各群の平均値±標準誤差で示した。統計解析の結果、20ヶ月齢、22ヶ月齢、24ヶ月齢のマウスの握力は、7ヶ月齢のマウスの握力と比較して、有意に低下していることがわかる。この結果により、上記系統のマウスでは、加齢に伴う筋力の低下を観察することができることが確認された。<Test Example 1>
Decrease in muscular strength due to aging of C57BL / 6J male mice In order to confirm the aging changes in muscular strength of C57BL / 6J male mice (Nippon Charles River Co., Ltd.), the transition of the total value of limb grip strength as an index was examined. Total limb grip strength at 7 months (23), 20 months (22), 22 months (7) and 24 months (7), grip strength measuring device (MK-380S, Muromachi Machinery Co., Ltd.) It was measured using the company) and used as the grip strength. Dunnett's multiple comparison test was used for the significance test. The grip strength measurement results of each group of 7 months old (7M), 20 months old (20M), 22 months old (22M) and 24 months old (24M) are shown in FIG. 1 (*: P <0.05, **). : P <0.01, comparison with 7 months old). The results are shown by the mean ± standard error of each group. As a result of statistical analysis, it can be seen that the grip strength of the 20-month-old, 22-month-old, and 24-month-old mice is significantly lower than that of the 7-month-old mouse. From this result, it was confirmed that the decrease in muscle strength with aging can be observed in the mice of the above strain.
<実施例1>
ソヤサポニン及びソヤサポゲノール粗画分の筋重量の減少抑制又は増加作用及び筋力の低下抑制又は増加作用
ソヤサポニン及びソヤサポゲノール粗画分が、加齢に伴う筋力低下に対し、筋力の低下抑制又は増加効果を示すか否かをマウスの四肢の握力を測定することで評価した。同時にマウス後肢の筋重量への減少抑制又は増加効果があるか否かに関しても検討した。ソヤサポゲノール粗画分は、調製例1で調製したものを用いた。<Example 1>
Suppression or increase of muscle weight and suppression or increase of muscle strength of the coarse fractions of soyasaponin and soyasapogenol Whether the coarse fractions of soyasaponin and soyasapogenol show an effect of suppressing or increasing muscle weakness against aging-related muscle weakness Whether or not it was evaluated was evaluated by measuring the grip strength of the limbs of the mouse. At the same time, it was also examined whether or not there is an effect of suppressing or increasing the muscle weight of the hind limbs of mice. As the crude fraction of soyasapogenol, the one prepared in Preparation Example 1 was used.
(試験方法)
70週齢のC57BL/6J雄性マウス(日本チャールスリバー株式会社)を8週間予備飼育した。予備飼育後のマウス(老齢マウス)を、コントロール(control)群、ソヤサポニン群及びソヤサポゲノール群の3群に分けた。各群5〜8匹で評価した。
コントロール群にはCE−2飼料(日本クレア株式会社)を8週間(試験期間)自由摂食させた。ソヤサポニン群にはサポニンB−50(株式会社J−オイルミルズ製)が0.5重量%になるように配合したCE−2飼料を、またソヤサポゲノール群にはソヤサポゲノール粗画分を0.5重量%配合したCE−2飼料を8週間自由摂食させた。
試験期間終了後、マウスの体重、後肢の筋重量及び握力を測定した。握力はマウス四肢の握力合計値を、握力測定機器(MK−380S、室町機械株式会社)を用いて測定した。後肢の筋重量は試験終了時に、腓腹筋、ヒラメ筋、足底筋、前脛骨筋、長趾伸筋及び大腿四頭筋を採取し、重量を測定した。筋重量の評価指標として、体重当たりの両後肢筋重量(腓腹筋、ヒラメ筋、足底筋、前脛骨筋、長趾伸筋及び大腿四頭筋の合計重量)の割合を求めた。有意差検定にはDunnettの多重比較検定を用いた。有意水準P<0.05を有意差ありとした。(Test method)
A 70-week-old C57BL / 6J male mouse (Japan Charles River Co., Ltd.) was preliminarily bred for 8 weeks. Pre-reared mice (aged mice) were divided into three groups: control group, soyasaponin group, and soyasapogenol group. Evaluation was performed on 5 to 8 animals in each group.
The control group was allowed to freely feed the CE-2 feed (Nippon Claire Co., Ltd.) for 8 weeks (test period). The soyasaponin group contains a CE-2 feed containing 0.5% by weight of saponin B-50 (manufactured by J-Oil Mills Co., Ltd.), and the soyasapogenol group contains 0.5% by weight of a crude soyasapogenol fraction. The compounded CE-2 feed was freely fed for 8 weeks.
At the end of the test period, mouse body weight, hind limb muscle weight and grip strength were measured. As for the grip strength, the total grip strength of the limbs of the mouse was measured using a grip strength measuring device (MK-380S, Muromachi Kikai Co., Ltd.). At the end of the test, the muscle weights of the hind limbs were measured by collecting the gastrocnemius muscle, soleus muscle, plantaris muscle, tibialis anterior muscle, extensor digitorum longus muscle, and quadriceps femoris. As an evaluation index of muscle weight, the ratio of both hind limb muscle weights (total weight of gastrocnemius muscle, soleus muscle, plantaris muscle, tibialis anterior muscle, extensor digitorum longus muscle and quadriceps muscle) was calculated. Dunnett's multiple comparison test was used for the significance test. A significance level P <0.05 was considered to be significantly different.
(結果)
1−1 握力測定結果
各群について、試験終了時の握力を試験開始時の握力で除した握力変化率(試験終了時の握力/試験開始時の握力)を求めた。コントロール群、ソヤサポニン群及びソヤサポゲノール群の各群の握力変化率を図2に示す(**:P<0.01、コントロール群との比較)。図2に示す結果は、各群の平均値±標準誤差で示した。統計解析の結果、コントロール群と比較して、ソヤサポニン群で有意に握力の増加が確認され、ソヤサポゲノール群でも握力の増加が確認された。(result)
1-1 Grip strength measurement results For each group, the rate of change in grip strength (grip strength at the end of the test / grip strength at the start of the test) was calculated by dividing the grip strength at the end of the test by the grip strength at the start of the test. The rate of change in grip strength of each group of the control group, soyasaponin group and soyasapogenol group is shown in FIG. 2 (**: P <0.01, comparison with the control group). The results shown in FIG. 2 are shown by the mean value ± standard error of each group. As a result of statistical analysis, a significant increase in grip strength was confirmed in the soyasaponin group as compared with the control group, and an increase in grip strength was also confirmed in the soyasapogenol group.
1−2 筋重量測定結果
各群について、試験終了時の両後肢筋重量を体重で除した、体重当たりの両後肢筋重量の割合(両後肢筋重量/体重)を求めた。コントロール群、ソヤサポニン群及びソヤサポゲノール群の各群の体重当たりの両後肢筋重量の割合を図3に示す。図3に示す結果は、各群の平均値±標準誤差で示した。統計解析の結果、コントロール群と比較して、ソヤサポニン群及びソヤサポゲノール群で、体重当たりの両後肢筋重量の割合の増加が確認された。1-2 Muscle Weight Measurement Results For each group, the ratio of both hindlimb muscle weights per body weight (both hindlimb muscle weights / body weight) was determined by dividing the weights of both hindlimb muscles at the end of the test by body weight. The ratio of the muscle weights of both hind limbs to the body weight of each of the control group, the soyasaponin group, and the soyasapogenol group is shown in FIG. The results shown in FIG. 3 are shown by the mean value ± standard error of each group. As a result of statistical analysis, an increase in the ratio of both hind limb muscle weights per body weight was confirmed in the soyasaponin group and the soyasapogenol group as compared with the control group.
以上より、ソヤサポニン類及びソヤサポゲノール類に、加齢に伴う筋力低下を抑制又は筋力を増加させて筋力を維持する効果があることが確認された。また、ソヤサポニン類及びソヤサポゲノール類に体重当たりの後肢筋重量の割合を増加させる効果が確認された。 From the above, it was confirmed that soyasaponins and soyasapogenols have the effect of suppressing aging-related muscle weakness or increasing muscular strength to maintain muscular strength. In addition, it was confirmed that soyasaponins and soyasapogenols have the effect of increasing the ratio of hind limb muscle weight to body weight.
<実施例2>
筋タンパク質合成量及び筋合成シグナルの評価(ソヤサポゲノール粗画分)
(試験方法)
(試薬)
ポンソーS溶液はSigma−Aldrich社から購入した。カルボキシメチルセルロースナトリウム(CMC−Na)、Extra PAGE One Precast Gel、Blocking oneはナカライテスク株式会社から購入した。Tissue Protein Extraction Reagent、Protease inhibitor cocktail kit、Pierce BCA protein assay kitは、サーモフィッシャーサイエンティフィック社から購入した。ピューロマイシンはInvivoGen社から、Anti−puromycinは、Millipore社から購入した。Anti−β−actin、Anti−mouse IgG, HRP−linked Antibody、Anti−rabbit IgG, HRP−linked Antibody、Phospho−p70 S6 Kinase(Thr389) Sandwich ELISA Kitは、Cell signaling Technolog社から購入した。PVDFメンブレンは、Invitrogen社から、ECL Western Blotting Detection Reagentsは、General Electric Company社から購入した。ソヤサポゲノール粗画分は、調製例1で調製したものを用いた。<Example 2>
Evaluation of muscle protein synthesis amount and muscle synthesis signal (Soyasapogenol crude fraction)
(Test method)
(reagent)
The Ponso S solution was purchased from Sigma-Aldrich. Sodium Carboxymethyl Cellulose (CMC-Na), Extra PAGE One Precast Gel, and Blocking one were purchased from Nacalai Tesque, Inc. The Tissue Protein Assay Reagent, Protein assay kit, and Pierce BCA protein assay kit were purchased from Thermo Fisher Scientific. Puromycin was purchased from InvivoGen and Anti-puromycin was purchased from Millipore. Anti-β-actin, Anti-mouse IgG, HRP-linked Antibody, Anti-rabbit IgG, HRP-linked Antibody, Phospho-p70 S6 Kinase (Thr389) Sandwich. PVDF membranes were purchased from Invitrogen and ECL Western Blotting Detection Reagents from General Electric Company. As the crude fraction of soyasapogenol, the one prepared in Preparation Example 1 was used.
(動物)
雄性7週齢C57BL6Jマウスを日本クレア株式会社から購入し、1週間の馴化期間の後、実験に供した。動物は、空調設備のある飼育室(温度23.5±1.0℃、湿度55±10%、換気回数12〜15回/時間、照明7:00−19:00/日)で飼育した。馴化期間中は、市販飼料(CE−2、日本クレア株式会社)及び水道水を自由に摂取させた。(animal)
Male 7-week-old C57BL6J mice were purchased from Japan Claire Co., Ltd. and subjected to experiments after a 1-week acclimation period. Animals were bred in an air-conditioned breeding room (temperature 23.5 ± 1.0 ° C., humidity 55 ± 10%, ventilation frequency 12 to 15 times / hour, lighting 7: 00-19: 00 / day). During the acclimation period, commercial feed (CE-2, Japan Claire Co., Ltd.) and tap water were allowed to be freely ingested.
馴化期間終了後、30匹のマウスを、以下の3群に分けた。
飽食群(Cont.)n=6
絶食群(Fast.)n=12
絶食+ソヤサポゲノール粗画分群(Fast.+SS)n=12
飽食群を除いた2群に対して、24時間の絶食を行った。絶食終了後に、絶食直後、絶食から7時間後、絶食から22時間後の3回に分けて、飽食群及び絶食群には0.5%CMC−Na水溶液を、絶食+ソヤサポゲノール粗画分群には、0.5%CMC−Na水溶液に懸濁した26mg/kg(1回あたり、体重1kgあたり26mg)のソヤサポゲノール粗画分をそれぞれ経口投与した(ソヤサポゲノール粗画分の投与量は、1日あたり、体重1kgあたり78mg)。絶食から23時間後に全群に対して、1.25mMのピューロマイシン水溶液を200μL/headで腹腔内投与した。ピューロマイシン投与時に腹腔内から溶液が漏れた個体、麻酔下での開腹時に腹腔内出血が確認された個体は、ピューロマイシンの組織中への取り込みに影響があると考え、この段階で解析対象から除外した。絶食から24時間後の試験終了後、腓腹筋を採取し、−80℃で凍結保存した。After the acclimation period was completed, 30 mice were divided into the following three groups.
Satiety group (Cont.) N = 6
Fasting group (Fast.) N = 12
Fasting + Soyasapogenol crude fraction group (Fast. + SS) n = 12
Two groups, excluding the satiety group, were fasted for 24 hours. After the end of the fast, immediately after the fast, 7 hours after the fast, and 22 hours after the fast, divide into 3 times, 0.5% CMC-Na aqueous solution for the fasting group and the fasting group, and the fasting + soyasapogenol crude fraction group. , 26 mg / kg (26 mg / kg body weight per dose) suspended in a 0.5% CMC-Na aqueous solution was orally administered (the dose of the crude soyasapogenol fraction was per day). 78 mg per kg of body weight). Twenty-three hours after fasting, a 1.25 mM puromycin aqueous solution was intraperitoneally administered at 200 μL / head to all groups. Individuals whose solution leaked from the abdominal cavity during administration of puromycin and individuals in which intra-abdominal bleeding was confirmed during laparotomy under anesthesia were excluded from analysis at this stage because they were considered to affect the uptake of puromycin into tissues. did. After the test was completed 24 hours after the fast, the gastrocnemius muscle was collected and cryopreserved at -80 ° C.
採取した腓腹筋について、下記方法でタンパク質合成量を測定した。また、腓腹筋中のp70S6キナーゼ(p70S6K)について、389番目のスレオニン(T389)がリン酸化されたp70S6K(リン酸化型p70S6K(T389))の量を測定した。 The amount of protein synthesis of the collected gastrocnemius muscle was measured by the following method. In addition, with respect to p70S6 kinase (p70S6K) in the gastrocnemius muscle, the amount of p70S6K (phosphorylated p70S6K (T389)) in which threonine (T389) at position 389 was phosphorylated was measured.
(腓腹筋中のタンパク質合成量の測定)
腓腹筋中のタンパク質合成量の測定はsurface sensing of translation(SUnSET)法を用いて実施した(Nat Methods. 2009 Apr;6(4):275−7)。マウスの腓腹筋を氷冷したProtease inhibitor cocktail、EDTAを含むTissue protein extraction reagentでホモジナイズした後、10,000rpm、10min、4℃で遠心し、上清を回収した。上清について、Pierce BCA protein assay kitを用いてタンパク質濃度定量を実施し、ウエスタンブロット用にSDS化を行った。得られた試料をタンパク質濃度10μg/10μLに調製後、Extra PAGE One Precast Gelに10μLをアプライし、電気泳動装置(Atto株式会社)を用いて電気泳動を行った。泳動完了後、ブロッティング装置を用いてPVDFメンブレンに転写を行った。ポンソーS溶液による染色で転写されたタンパク質量に差がないことを確認した後、Blocking one存在下でAnti−puromycin(1:3000)、Anti−β−actin(1:2000)を添加し、4℃で18時間インキュベーションを行った。室温でAnti−rabbit IgG,HRP−linked Antibody(1:10000)を添加し、2時間インキュベーション後に、ECL Western Blotting Detection Reagentsを添加し、FUSIONSOLOを用いてバンドの検出及び解析を実施した。尚、結果は絶食群(Fast.)を100とした相対値で表した。(Measurement of protein synthesis in gastrocnemius muscle)
The amount of protein synthesis in the gastrocnemius muscle was measured using the surface sensing of translation (SUNSET) method (Nat Methods. 2009 Apr; 6 (4): 275-7). The gastrocnemius muscle of mice was homogenized with ice-cooled Protein inhibitor cocktail and EDTA-containing Tissue protease reagent, and then centrifuged at 10,000 rpm, 10 min, and 4 ° C. to collect the supernatant. For the supernatant, protein concentration was quantified using the Pierce BCA protein assay kit, and SDS was performed for Western blotting. The obtained sample was prepared to have a protein concentration of 10 μg / 10 μL, 10 μL was applied to Extra PAGE One Precast Gel, and electrophoresis was performed using an electrophoresis device (Atto Co., Ltd.). After the electrophoresis was completed, the transfer was performed on the PVDF membrane using a blotting device. After confirming that there was no difference in the amount of protein transferred by staining with Ponso S solution, Anti-puromycin (1: 3000) and Anti-β-actin (1: 2000) were added in the presence of Blocking one, and 4 Incubation was carried out at ° C. for 18 hours. Anti-rabbit IgG and HRP-linked antibody (1: 10000) were added at room temperature, and after incubation for 2 hours, ECL Western Blotting Detection Reagents were added, and band detection and analysis was performed using FUSIONSOLO. The results were expressed as relative values with the fasting group (Fast.) As 100.
(腓腹筋中のリン酸化型p70S6K(T389)量の測定)
腓腹筋中のリン酸化型p70S6K(T389)量の測定は、ELISA Kitを用いて添付のプロトコルに従い実施した。リン酸化型p70S6K(T389)量として、試料中のタンパク質濃度あたりのリン酸化型p70S6K(T389)量を求めた。尚、結果は絶食群(Fast.)を100とした相対値で表した。(Measurement of phosphorylated p70S6K (T389) amount in gastrocnemius muscle)
The amount of phosphorylated p70S6K (T389) in the gastrocnemius muscle was measured using an ELISA Kit according to the attached protocol. As the amount of phosphorylated p70S6K (T389), the amount of phosphorylated p70S6K (T389) per protein concentration in the sample was determined. The results were expressed as relative values with the fasting group (Fast.) As 100.
(統計解析)
得られた数値は平均値±標準誤差で示した。ソヤサポゲノール粗画分の有効性を確認する際の統計学的検定は、one−way ANOVAで分散分析の後、Dunnett’s testを用いて絶食群との多重比較検定を実施した。有意水準P<0.05を有意差ありとした。なお、これらの解析は全てエクセル統計(BellCurve社製)を用いて実施した。(Statistical analysis)
The obtained values are shown as mean ± standard error. As a statistical test for confirming the effectiveness of the crude soyasapogenol fraction, analysis of variance was performed by one-way ANOVA, and then a multiple comparison test with the fasting group was performed using Dunnett's test. A significance level P <0.05 was considered to be significantly different. All of these analyzes were performed using Excel statistics (manufactured by BellCurve).
(結果)
図4は、ソヤサポゲノール粗画分を投与したマウスの腓腹筋におけるタンパク質合成量を示すグラフである(*:P<0.05、絶食群との比較)。図5は、ソヤサポゲノール粗画分を投与したマウスの腓腹筋におけるリン酸化型p70S6K(T389)の量を示すグラフである(*:P<0.05、絶食群との比較)。図4及び図5に示すグラフのデータは、平均±標準誤差で示される(n=6又は12)。
図4の飽食群(Cont.)と絶食群(Fast.)との比較から、絶食によりタンパク質合成量が減少することが分かる。絶食群と比較して、絶食+ソヤサポゲノール粗画分群(Fast.+SS)で、1.38倍の有意な筋タンパク質合成量の増加が確認された(図4)。
また、リン酸化型p70S6K(T389)量も絶食群(Fast.)と比較して、絶食+ソヤサポゲノール粗画分群(Fast.+SS)で有意な増加が確認された(図5)。p70S6Kがリン酸化されることは、筋重量の増加に重要である。リン酸化型p70S6K(T389)量の増加により、筋タンパク質合成量が増加したと考えられた。(result)
FIG. 4 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice to which the crude soyasapogenol fraction was administered (*: P <0.05, comparison with the fasting group). FIG. 5 is a graph showing the amount of phosphorylated p70S6K (T389) in the gastrocnemius muscle of mice to which the crude soyasapogenol fraction was administered (*: P <0.05, comparison with the fasting group). The graph data shown in FIGS. 4 and 5 are shown as mean ± standard error (n = 6 or 12).
From the comparison between the satiety group (Cont.) And the fasting group (Fast.) In FIG. 4, it can be seen that the amount of protein synthesis decreases due to fasting. Compared with the fasting group, a significant increase in muscle protein synthesis of 1.38 times was confirmed in the fasting + soyasapogenol crude fraction group (Fast. + SS) (Fig. 4).
In addition, the amount of phosphorylated p70S6K (T389) was also significantly increased in the fasting + soyasapogenol crude fraction group (Fast. + SS) as compared with the fasting group (Fast.) (Fig. 5). Phosphorylation of p70S6K is important for increasing muscle weight. It was considered that the amount of muscle protein synthesis increased due to the increase in the amount of phosphorylated p70S6K (T389).
<実施例3>
筋タンパク質合成量の評価(4種のトリテルペノイド化合物)
ソヤサポゲノールA、ソヤサポゲノールB、マスリン酸又はオレアノール酸の4種のトリテルペノイドをマウスに摂取させて、タンパク質合成に与える効果を調べた。ソヤサポゲノールA、ソヤサポゲノールB、マスリン酸、オレアノール酸は、Sigma−Aldrich社から購入した。<Example 3>
Evaluation of muscle protein synthesis (4 types of triterpenoid compounds)
Four types of triterpenoids, soyasapogenol A, soyasapogenol B, maslinic acid or oleanolic acid, were ingested by mice, and their effects on protein synthesis were investigated. Soyasapogenol A, Soyasapogenol B, maslinic acid, and oleanolic acid were purchased from Sigma-Aldrich.
(試験方法)
実施例2と同じ動物(雄性7週齢C57BL6Jマウス)を、実施例2と同じ方法で飼育して馴化させた。馴化期間終了後、54匹のマウスを、以下の6群(各群9匹)に分けた。
飽食群(Cont.)、絶食群(Fast.)、絶食+ソヤサポゲノールA群(Fast.+SSA)、絶食+ソヤサポゲノールB群(Fast.+SSB)、絶食+マスリン酸群(Fast.+MA)、絶食+オレアノール酸群(Fast.+OA)
飽食群を除いた5群に対して、24時間の絶食を行った。絶食終了後に、絶食直後、絶食から7時間後、絶食から22時間後の3回に分けて、飽食群及び絶食群には0.5%CMC−Na水溶液を、絶食+トリテルペノイド群には、0.5%CMC−Na水溶液に懸濁した26mg/kg(1回あたり、体重1kgあたり26mg)のトリテルペノイド(ソヤサポゲノールA、ソヤサポゲノールB、マスリン酸又はオレアノール酸)を経口投与した。絶食から23時間後に全群に対して、1.25mMのピューロマイシン水溶液を200μL/headで腹腔内投与した。ピューロマイシン投与時に腹腔内から溶液が漏れた個体、麻酔下での開腹時に腹腔内出血が確認された個体は、ピューロマイシンの組織中への取り込みに影響があると考え、この段階で解析対象から除外した。絶食から24時間後の試験終了後、腓腹筋を採取し、−80℃で凍結保存した。採取した腓腹筋について、実施例2と同じ方法でタンパク質合成量を測定した。(Test method)
The same animals as in Example 2 (male 7-week-old C57BL6J mice) were bred and acclimated in the same manner as in Example 2. After the acclimation period was completed, 54 mice were divided into the following 6 groups (9 mice in each group).
Saturation group (Cont.), Fasting group (Fast.), Fasting + Soyasapogenol A group (Fast. + SSA), Fasting + Soyasapogenol B group (Fast. + SSB), Fasting + Maslinic acid group (Fast. + MA), Fasting + Oleanol Acid group (Fast. + OA)
Five groups, excluding the satiety group, were fasted for 24 hours. After the end of the fast, immediately after the fast, 7 hours after the fast, and 22 hours after the fast, divide into 3 times, 0.5% CMC-Na aqueous solution for the fasting group and the fasting group, and 0 for the fasting + triterpenoid group. A 26 mg / kg (26 mg / kg body weight per dose) triterpenoid (Soyasapogenol A, Soyasapogenol B, maslinic acid or oleanolic acid) suspended in a 5.5% CMC-Na aqueous solution was orally administered. Twenty-three hours after fasting, a 1.25 mM puromycin aqueous solution was intraperitoneally administered at 200 μL / head to all groups. Individuals whose solution leaked from the abdominal cavity during administration of puromycin and individuals in which intra-abdominal bleeding was confirmed during laparotomy under anesthesia were excluded from analysis at this stage because they were considered to affect the uptake of puromycin into tissues. did. After the test was completed 24 hours after the fast, the gastrocnemius muscle was collected and cryopreserved at -80 ° C. For the collected gastrocnemius muscle, the amount of protein synthesis was measured by the same method as in Example 2.
(統計解析)
得られた数値は平均値±標準誤差で示した。4種のトリテルペノイドの効果を比較する際には、one−way ANOVAで分散分析の後、Tukey’s testを用いて多重比較検定を実施した。有意水準P<0.05を有意差ありとした。なお、これらの解析は全てエクセル統計(BellCurve社製)を用いて実施した。(Statistical analysis)
The obtained values are shown as mean ± standard error. When comparing the effects of the four triterpenoids, analysis of variance was performed with one-way ANOVA, and then multiple comparison tests were performed using Tukey's test. A significance level P <0.05 was considered to be significantly different. All of these analyzes were performed using Excel statistics (manufactured by BellCurve).
(結果)
図6は、ソヤサポゲノールA、ソヤサポゲノールB、マスリン酸又はオレアノール酸を投与したマウスの腓腹筋におけるタンパク質合成量を示すグラフである(*:P<0.05、各群との比較)。図6に示すグラフのデータは、平均±標準誤差で示される(n=9)。
絶食群(Fast.)と比較して、絶食+ソヤサポゲノールA群(Fast.+SSA)及び絶食+ソヤサポゲノールB群(Fast.+SSB)に有意な筋タンパク質合成量の増加が確認された。4種のトリテルペノイド間の比較に関しては、絶食+ソヤサポゲノールA群に、絶食+オレアノール酸群(Fast.+OA)と比較して有意な筋タンパク質合成量の増加が確認された。絶食+ソヤサポゲノールA群は、絶食+マスリン酸群(Fast.+MA)と比較して筋タンパク質合成量の増加傾向が確認された。絶食+ソヤサポゲノールB群は絶食+マスリン酸群及び絶食+オレアノール酸群と比較して、有意な筋タンパク質合成量の増加が確認された(図6)。(result)
FIG. 6 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice to which soyasapogenol A, soyasapogenol B, maslinic acid or oleanolic acid was administered (*: P <0.05, comparison with each group). The data in the graph shown in FIG. 6 is shown as mean ± standard error (n = 9).
A significant increase in muscle protein synthesis was confirmed in the fasting + soyasapogenol A group (Fast. + SSA) and the fasting + soyasapogenol B group (Fast. + SSB) as compared with the fasting group (Fast.). Regarding the comparison between the four triterpenoids, a significant increase in muscle protein synthesis was confirmed in the fasting + soyasapogenol A group as compared with the fasting + oleanolic acid group (Fast. + OA). It was confirmed that the fasting + soyasapogenol A group tended to increase the amount of muscle protein synthesis as compared with the fasting + maslinic acid group (Fast. + MA). A significant increase in muscle protein synthesis was confirmed in the fasting + soyasapogenol B group as compared with the fasting + maslinic acid group and the fasting + oleanolic acid group (Fig. 6).
<実施例4>
正常ヒト骨格筋筋芽細胞(HSMM)(LONZA社)を用いて、被験物質による筋管細胞分化促進効果を調べた。
被験物質には、調製例1で製造したソヤサポゲノール粗画分を用いた。被験物質(4μg/mL)の存在下で、n=3で2日間、HSMMの筋管分化誘導を行った。得られた細胞についてMHC染色による筋管染色及びHoechst33342染色による核染色を行い、筋管分化率を定量化した。<Example 4>
Using normal human skeletal myoblasts (HSMM) (LONZA), the effect of the test substance on promoting myotube cell differentiation was investigated.
As the test substance, the crude fraction of soyasapogenol produced in Preparation Example 1 was used. In the presence of the test substance (4 μg / mL), HSMM was induced to differentiate into myotubes at n = 3 for 2 days. The obtained cells were subjected to myotube staining by MHC staining and nuclear staining by Hoechst33342 staining to quantify the myotube differentiation rate.
(被験サンプルの調製)
ソヤサポゲノール粗画分はジメチルスルホキシド(DMSO)に溶解した。これを0.1%DMSO含有分化培地で順次5倍希釈し、試験に用いた。コントロール(Vehicleコントロール)として、0.1%DMSO含有分化培地を用いた。分化培地には、2% HORSE SERUM(サーモフィッシャーサイエンティフィック社)添加DMEM:F−12培地(Lonza社)を使用した。陽性対照として、0.5μM LDN−193189(Sigma−Aldrich社)添加0.1%DMSO含有分化培地を用いた。(Preparation of test sample)
The crude soyasapogenol fraction was dissolved in dimethyl sulfoxide (DMSO). This was sequentially diluted 5-fold with a differentiation medium containing 0.1% DMSO and used in the test. As a control (Vehicle control), a differentiation medium containing 0.1% DMSO was used. As the differentiation medium, DMEM: F-12 medium (Lonza) supplemented with 2% HORSE SERUM (Thermo Fisher Scientific) was used. As a positive control, a differentiation medium containing 0.1% DMSO containing 0.5 μM LDN-193189 (Sigma-Aldrich) was used.
(Growth Factor Reduced(GFR)Matrigel Matrixコート)
筋管分化誘導時は96ウェルプレートをGFR Matrigel Matrix(Corning社)でコートして用いた。GFR FR Matrigel Matrixを4℃で一晩解凍した後、DMEM:F−12培地(4℃)で100倍希釈し、氷上で96ウェルプレートの各ウェルに0.1mLずつ分注し、室温で1時間インキュベートした。溶液を吸引してDMEM:F−12培地(0.1mL)でリンスし、細胞播種に用いた。(Growth Factor Rediced (GFR) Matrigel Matrix Coat)
At the time of inducing myotube differentiation, a 96-well plate was coated with GFR Matrix Matrix (Corning) and used. After thawing GFR FR Matrix Matrix overnight at 4 ° C, dilute 100-fold with DMEM: F-12 medium (4 ° C), dispense 0.1 mL into each well of a 96-well plate on ice, and 1 at room temperature. Incubated for hours. The solution was aspirated and rinsed with DMEM: F-12 medium (0.1 mL) and used for cell seeding.
(細胞前培養)
HSMMは、増殖培地(20%FBS(ウシ胎児血清)(サーモフィッシャーサイエンティフィック社)、4%ultroserG(PALL社)、1%Antibiotic−Antimycotic Mixed Stock solution(ナカライテスク株式会社)添加DMEM(high glucose)(Sigma−Aldrich社))を用いて前培養した。70%コンフルエントになった時点でTrypsin−EDTA(0.05%)、phenol red(いずれもサーモフィッシャーサイエンティフィック社)を用いて細胞を剥離し、増殖培地を用いて5,000cells/0.1mL/wellとなるようGFR Matrigel Matrixコート96ウェルプレートに播種し、CO2インキュベーターで培養した。(Pre-cell culture)
HSMM is DMEM (high glucose) supplemented with growth medium (20% FBS (fetal bovine serum) (Thermo Fisher Scientific), 4% ultraserG (PALL), 1% Antibiotic-Antimycotic Mixed Stock solution (Nacalai Tesque, Inc.). ) (Sigma-Aldrich)) was precultured. When the cells reached 70% confluence, the cells were detached using Trypsin-EDTA (0.05%) and phenol red (both from Thermo Fisher Scientific), and 5,000 cells / 0.1 mL using a growth medium. The cells were seeded on a GFR Matrigel Matrix coated 96-well plate so as to be / well, and cultured in a CO 2 incubator.
(被験物質の処理(筋管分化誘導))
GFR Matrigel Matrixコート96ウェルプレートにHSMMを播種翌日、ソヤサポゲノール粗画分添加分化培地(0.1mL)に交換し、2日間CO2インキュベーターで培養した。コントロールは、ソヤサポゲノール粗画分添加分化培地の代わりにVehicleコントロール(0.1%DMSO含有分化培地)を使用して培養した。(Treatment of test substance (induction of myotube differentiation))
HSMM was seeded on a GFR Matrigel Matrix coated 96-well plate. The day after sowing, the cells were replaced with soyasapogenol crude fractionated differentiation medium (0.1 mL) and cultured in a CO 2 incubator for 2 days. Controls were cultured using Vehicle Control (0.1% DMSO-containing differentiation medium) instead of Soyasapogenol crude fractionated differentiation medium.
(免疫染色)
培養後に、培地を除去した後、4%パラホルムアルデヒド(PFA)(4℃)を0.1mL加え、4℃で15分間インキュベートして細胞を固定した。次に、Dulbecco’s Phosphate−Buffered Saline(DPBS)(サーモフィッシャーサイエンティフィック社)0.1mLを用いてウェルを3回洗浄した後、ブロッキング/膜透過溶液(3%BSA(ウシ血清アルブミン)/0.3%Triton−X 100/DPBS)を0.1mL加え、室温で30分間インキュベートした。次に、一次抗体溶液(一次抗体を1/150量、3%BSA/DPBSに添加して調製)0.05mLに交換し、4℃でオーバーナイトインキュベートした。3%BSA/DPBS溶液0.1mLで3回洗浄した後、二次抗体溶液(二次抗体を1/500量、Hoechst33342を1/1000量、3%BSA/DPBSに添加して調製)0.05mLに交換し、室温で2時間インキュベートした。DPBS0.1mLで3回洗浄した後、DPBS0.1mLを加え、Operetta CLS(登録商標)(パーキンエルマー社)で画像撮影及び定量解析を行った。上記一次抗体にはAnti−Myosin−Heavy Chain Purified(抗MHC抗体)(Affymetrix社)を、二次抗体にはGoast anti−Mouse IgG2b Secondary Antibody, Alexa Fluor 555 conjugate(サーモフィッシャーサイエンティフィック社)をそれぞれ使用した。(Immunostaining)
After culturing, the medium was removed, 0.1 mL of 4% paraformaldehyde (PFA) (4 ° C.) was added, and the cells were fixed by incubating at 4 ° C. for 15 minutes. The wells were then washed 3 times with 0.1 mL of Dulbecco's Phosphate-Buffered Saline (DPBS) (Thermo Fisher Scientific), followed by a blocking / membrane permeation solution (3% BSA (bovine serum albumin) /). 0.3% Triton-
(イメージング解析)
Operetta CLS(登録商標)を用いて、各ウェル中央9視野を、10倍対物レンズを用いて撮影した。画像を取得後、核及びMHC陽性の核を検出し、カウントした後、fusion index(%of MHC陽性核=100×MHC陽性核数/総核数)を算出し、筋管分化率を定量化した。(Imaging analysis)
Using an Operetta CLS®, 9 visual fields in the center of each well were photographed with a 10x objective lens. After acquiring images, nuclei and MHC-positive nuclei are detected and counted, and then fusion index (% of MHC-positive nuclei = 100 x MHC-positive nuclei / total number of nuclei) is calculated to quantify the myotube differentiation rate. did.
(統計解析)
Student’s t−testにより比較試験群間(コントロールvsソヤサポゲノール粗画分添加群)の有意差検定を行った。両側検定を行い、P<0.05を有意差有とした。(Statistical analysis)
A significant difference test was performed between the comparative test groups (control vs. soyasapogenol crude fraction addition group) by Student's t-test. A two-sided test was performed, and P <0.05 was considered significant.
(結果)
図7は、正常ヒト骨格筋筋芽細胞を用いて、ソヤサポゲノール粗画分による筋管細胞分化促進効果を調べた結果を示すグラフである(*:P<0.05、コントロールとの比較)。図7のソヤサポゲノールは、ソヤサポゲノール粗画分添加群である。ソヤサポゲノール粗画分添加群では、コントロールと比較してfusion index(%of MHC陽性核)が大きく、筋管分化率が高かった。ソヤサポゲノール粗画分により、正常ヒト骨格筋筋芽細胞から筋管細胞への分化が促進された。(result)
FIG. 7 is a graph showing the results of examining the effect of promoting myotube cell differentiation by the crude soyasapogenol fraction using normal human skeletal myoblasts (*: P <0.05, comparison with control). The soyasapogenol in FIG. 7 is a group to which the coarse fraction of soyasapogenol was added. In the soyasapogenol crude fraction-added group, the fusion index (% of MHC-positive nuclei) was larger and the myotube differentiation rate was higher than that of the control. The crude soyasapogenol fraction promoted the differentiation of normal human skeletal myoblasts into myotube cells.
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018087232 | 2018-04-27 | ||
JP2018087232 | 2018-04-27 | ||
PCT/JP2019/017413 WO2019208627A1 (en) | 2018-04-27 | 2019-04-24 | Composition for preventing decrease in muscle mass, preventing decrease in muscular power, increasing muscle mass or enhancing muscular power |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019208627A1 true JPWO2019208627A1 (en) | 2021-05-27 |
JP7227962B2 JP7227962B2 (en) | 2023-02-22 |
Family
ID=68293951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020515521A Active JP7227962B2 (en) | 2018-04-27 | 2019-04-24 | Composition for suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7227962B2 (en) |
CN (1) | CN112055544A (en) |
TW (1) | TWI821282B (en) |
WO (1) | WO2019208627A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010047529A (en) * | 2008-08-22 | 2010-03-04 | Lion Corp | Muscular atrophy inhibitor |
JP2012041294A (en) * | 2010-08-18 | 2012-03-01 | Fuji Oil Co Ltd | Spinal cord injury repair promoter |
IN2013CN09358A (en) * | 2011-06-28 | 2015-08-14 | J Oil Mills Inc | |
TW201408302A (en) * | 2012-08-22 | 2014-03-01 | J Oil Mills Inc | Soyasapogenol composition |
SG11201708158PA (en) * | 2015-04-27 | 2017-11-29 | Suntory Holdings Ltd | Composition for suppressing muscular fatty change |
KR20170054115A (en) * | 2015-11-09 | 2017-05-17 | 대한민국(농촌진흥청장) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis |
-
2019
- 2019-04-24 WO PCT/JP2019/017413 patent/WO2019208627A1/en active Application Filing
- 2019-04-24 CN CN201980028698.9A patent/CN112055544A/en active Pending
- 2019-04-24 JP JP2020515521A patent/JP7227962B2/en active Active
- 2019-04-26 TW TW108114655A patent/TWI821282B/en active
Non-Patent Citations (15)
Title |
---|
KIM, YONG-AN ET AL.: "Platycodon grandiflorum-derived saponin attenuates the eccentric exercise-induced muscle damage", FOOD AND CHEMICAL TOXICOLOGY, vol. Vol. 112 (2018), JPN6019029061, 26 December 2017 (2017-12-26), pages 150 - 156, ISSN: 0004840578 * |
ZHOU, ZHIYONG ET AL.: "Panax notoginseng saponins attenuate cardiomyocyte apoptosis through mitochondrial pathway in natura", PHYTOTHERAPY RESEARCH, vol. Vol. 32 (2018), JPN6019029063, 12 December 2017 (2017-12-12), pages 243 - 250, ISSN: 0004840579 * |
ZHOU, ZHI-YONG ET AL.: "Total saponins of Panax japonicus improve cancer cachexia in mice through inhibiting inflammatory re", CHINESE PHARMACOLOGICAL BULLETIN, vol. Vol. 34 (2018), No. 4, JPN6019029066, 28 March 2018 (2018-03-28), pages 532 - 536, ISSN: 0004840577 * |
もみ処ブログ, 2017.08.31 [検索日 2022.07.20], インターネット:<URL:HTTPS://WWW.MOMIDOKORO.JP/BLOG/?P, JPN6022031851, ISSN: 0004840573 * |
保健指導リソースガイド, 2018.01.31 [検索日 2022.07.27], インターネット:<URL:HTTPS://TOKUTEIKENSHIN-, JPN6022031853, ISSN: 0004840575 * |
化学工業日報, JPN6022031855, 27 July 2012 (2012-07-27), pages 5, ISSN: 0004840576 * |
千寿会ブログ, 2015.02.03 [検索日 2022.07.20], インターネット:<URL:HTTP://WWW.SENJYUKAI.OR.JP/BLOG/B, JPN6022031850, ISSN: 0004840572 * |
塚本知玄: "大豆種子サポニン成分の化学構造の遺伝育種的改変", 日本食品科学工学会誌, vol. 59, no. 8, JPN6019029067, 2012, pages 429 - 434, ISSN: 0004840580 * |
大塚製薬 栄養ラボ, 2018.04.12 [検索日 2022.07.27], インターネット:<URL:HTTPS://WWW.OTSUKA.CO.JP/CMT, JPN6022031852, ISSN: 0004840574 * |
日本栄養・食糧学会大会講演要旨集, vol. 65, JPN6022031845, 2011, pages 136, ISSN: 0004840582 * |
日本栄養・食糧学会大会講演要旨集, vol. 71, JPN6022031843, 2017, pages 296, ISSN: 0004840581 * |
日本栄養・食糧学会近畿支部大会講演要旨集, vol. 52, JPN6022031846, 2013, pages 23, ISSN: 0004840583 * |
日本食品科学工学会大会講演集, vol. 60, JPN6022031848, 2013, pages 86, ISSN: 0004840585 * |
日本食品科学工学会誌, vol. 60, no. 9, JPN6022031847, 2013, pages 527 - 533, ISSN: 0004840584 * |
食品と開発, vol. 45, no. 8, JPN6022031849, 2010, pages 54 - 56, ISSN: 0004840586 * |
Also Published As
Publication number | Publication date |
---|---|
TW202005556A (en) | 2020-02-01 |
JP7227962B2 (en) | 2023-02-22 |
TWI821282B (en) | 2023-11-11 |
CN112055544A (en) | 2020-12-08 |
WO2019208627A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shih et al. | Effects of adlay on azoxymethane-induced colon carcinogenesis in rats | |
EP2604262A1 (en) | Composition comprising a reduced isoalpha acid, a mineral and a vitamin for use in the treatment of autoimmune diseases | |
WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
KR20080105023A (en) | Nutraceutical composition for the treatment of muscle wasting | |
TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
JP2021503878A (en) | Compositions and Methods Using Oleuropein or Curcumin for Muscle Quality and / or Muscle Mass | |
JP5080284B2 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND / OR TREATMENT OF BONE DISEASE, FUNCTIONAL FOOD, HEALTHY FOOD AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION, AND Root-periodontium formation promoter | |
US20160067270A1 (en) | Use of ginsenoside f2 for prophylaxis and treatment of liver disease | |
Klein | Preventive and therapeutic efficacy of halofuginone-lactate against Cryptosporidium parvum in spontaneously infected calves: a centralised, randomised, double-blind, placebo-controlled study | |
JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
JP6272646B2 (en) | A pharmaceutical composition for promoting bone formation containing a furofuran type lignan having an axial-equalary orientation, a pharmaceutical preparation containing the composition, a functional food and a health food containing the composition | |
JP6265335B2 (en) | Bone density increasing agent, osteoclast activity inhibitor, and bone remodeling improving agent | |
Simelane et al. | Lactogenic activity of rats stimulated by Gunnera perpensa L.(Gunneraceae) from South Africa | |
JP2019208461A (en) | Functional food | |
JP7227962B2 (en) | Composition for suppressing muscle mass loss, suppressing muscle weakness, increasing muscle mass, or increasing muscle strength | |
RU2322995C1 (en) | Biopreparation of veterinary indication and method for preventing gastro-intestinal diseases in neonatal calves due to its application | |
JP5903280B2 (en) | Intestinal regulating agent, bowel movement improving agent, and constipation improving agent | |
WO2021200996A1 (en) | Composition for ameliorating or preventing decreases in bone strength | |
Xu et al. | Loganin regulates glycolipid metabolism by influencing intestinal microbiota and AMPK signaling in obese mice | |
KR102689057B1 (en) | Pharmaceutical composition for preventing or treating obesity or cardiovascular diseases comprising Fangchinoline as an active ingredient | |
JP2015193547A (en) | Resveratrol heat treatment composition which has motion-like action | |
ES2661579A1 (en) | Composition for the control of weight through the modulation of the levels of peptides involved in satiety and/or appetite. (Machine-translation by Google Translate, not legally binding) | |
RU2473358C1 (en) | Composition possessing adaptogenic, hepatoprotective and immunomodulatory action | |
US20240091293A1 (en) | Immunity-enhancing composition containing syneilesis palmata extract as active ingredient | |
WO2021065661A1 (en) | Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210819 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7227962 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |